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Abstract
Skeletal muscle Akt activity stimulates muscle growth and imparts resistance to obesity, glucose intolerance and fatty liver
disease. We recently found that ursolic acid increases skeletal muscle Akt activity and stimulates muscle growth in non-
obese mice. Here, we tested the hypothesis that ursolic acid might increase skeletal muscle Akt activity in a mouse model of
diet-induced obesity. We studied mice that consumed a high fat diet lacking or containing ursolic acid. In skeletal muscle,
ursolic acid increased Akt activity, as well as downstream mRNAs that promote glucose utilization (hexokinase-II), blood
vessel recruitment (Vegfa) and autocrine/paracrine IGF-I signaling (Igf1). As a result, ursolic acid increased skeletal muscle
mass, fast and slow muscle fiber size, grip strength and exercise capacity. Interestingly, ursolic acid also increased brown fat,
a tissue that shares developmental origins with skeletal muscle. Consistent with increased skeletal muscle and brown fat,
ursolic acid increased energy expenditure, leading to reduced obesity, improved glucose tolerance and decreased hepatic
steatosis. These data support a model in which ursolic acid reduces obesity, glucose intolerance and fatty liver disease by
increasing skeletal muscle and brown fat, and suggest ursolic acid as a potential therapeutic approach for obesity and
obesity-related illness.
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Introduction
Ursolic acid is a lipophilic pentacyclic triterpenoid that
contributes to the waxy coats on apples, other fruits, and many
herbs, including some folkloric herbal medicines for diabetes [1–
4]. We recently identified ursolic acid in a screen for small
molecule inhibitors of skeletal muscle atrophy [5]. In that study,
we determined the effects of fasting and spinal cord injury on
skeletal muscle mRNA levels in humans, and used that informa-
tion to generate unbiased mRNA expression signatures of human
skeletal muscle atrophy. We then used these signatures to query
the Connectivity Map [6] for compounds whose expression
signatures negatively correlated with the signatures of human
muscle atrophy. Out of .1300 compounds in the Connectivity
Map, ursolic acid emerged as the most likely inhibitor of muscle
atrophy.
To test the hypothesis that ursolic acid might inhibit muscle
atrophy, we studied mice that had been fasted or undergone
surgical muscle denervation, and found that ursolic acid reduced
muscle atrophy [5]. We then investigated ursolic acid’s effect in the
absence of an atrophy stimulus by adding ursolic acid to standard
mouse chow for 5 weeks. In that setting, ursolic acid induced
skeletal muscle hypertrophy [5]. Since the protein kinase Akt (also
known as PKB) inhibits muscle atrophy and promotes muscle
hypertrophy [7–13], we examined ursolic acid’s effect on Akt. We
found that ursolic acid increased Akt activity in mouse skeletal
muscle and in cultured C2C12 skeletal myotubes [5]. In myotubes,
ursolic acid increased Akt activity at least in part by enhancing
ligand-dependent activation of the insulin receptor and insulin-like
growth factor I (IGF-I) receptor.
In addition to causing muscle hypertrophy, genetic interven-
tions that activate Akt specifically in skeletal muscle also increase
energy expenditure, reduce adiposity and blood glucose, and
impart resistance to diet-induced obesity, glucose intolerance and
fatty liver disease [8,9]. Similarly, we found that ursolic acid
reduced adiposity and blood glucose in non-obese mice [5], and
others found that ursolic acid reduces total body weight, white fat,
glucose intolerance and hepatic steatosis in high fat-fed mice
[14,15]. Based on these considerations, we hypothesized that
ursolic acid might increase skeletal muscle Akt activity in a mouse
model of diet-induced obesity, leading to muscle hypertrophy,
increased energy expenditure and thus, reduced obesity, glucose
intolerance and fatty liver disease. In the current study, we tested
this hypothesis, and found that ursolic acid increases not only
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39332skeletal muscle, but also another tissue that opposes diet-induced
obesity, brown fat.
Results
Ursolic acid increases skeletal muscle Akt activity, induces
skeletal muscle hypertrophy and increases exercise
capacity in a mouse model of diet-induced obesity
To investigate the effects of ursolic acid in diet-induced obese
mice, we provided 8-week-old male C57BL/6 mice ad libitum
access to a high fat diet or a high fat diet supplemented with 0.14%
ursolic acid for 6 weeks. This high fat diet (55% calories from fat)
is known to cause obesity, as well as glucose intolerance and fatty
liver disease [16,17]. After 6 weeks on these diets, we harvested
triceps muscle and examined steady-state Akt phosphorylation, a
marker of Akt activity [18]. We found that ursolic acid increased
Akt phosphorylation more than two-fold (Fig. 1A).
As an additional test of Akt activity, we measured levels of
hexokinase-II (Hk2) and vascular endothelial growth factor-A (Vegfa)
mRNAs; these transcripts are induced by Akt signaling in skeletal
muscle and encode proteins that promote glucose utilization and
blood vessel recruitment, respectively [8,10,19]. We found that
ursolic acid increased both Hk2 and Vegfa mRNAs (Fig. 1B). In our
previous study of non-obese mice, we found that ursolic acid also
increased the level of Igf1 mRNA in skeletal muscle [5]. Local Igf1
expression is an autocrine/paracrine mechanism that increases
skeletal muscle IGF-I/Akt signaling and thus muscle growth [20–
22]. We therefore examined ursolic acid’s effects on skeletal
muscle Igf1 mRNA in high fat-fed mice, and found that ursolic
acid increased it (Fig. 1B). These data provided further evidence
that ursolic acid stimulates skeletal muscle Akt activity.
Since Akt signaling promotes skeletal muscle hypertrophy [7–
13], we measured grip strength, muscle weight and muscle fiber
size. We found that ursolic acid increased grip strength and
skeletal muscle weight (Figs. 1C&D). We saw similar effects with
0.14% ursolic acid (Figs. 1C&D) and 0.27% ursolic acid (Fig. S1).
Ursolic acid also increased the size of both fast and slow skeletal
muscle fibers (Fig. 1E) without altering the ratio of fast to slow
fibers. Thus, consistent with increased skeletal muscle Akt activity,
ursolic acid induced skeletal muscle hypertrophy.
Since ursolic acid increased the size of both slow (oxidative) and
fast (glycolytic) muscle fibers, we asked whether it might improve
exercise capacity. To test this, we measured maximal running
distance on an exercise treadmill. We found that ursolic acid-
treated mice ran significantly farther than control mice (Fig. 2A).
Treadmill running also reflects cardiovascular function, which we
further evaluated by measuring resting blood pressure and heart
rate. Ursolic acid did not alter blood pressure (Fig. 2B), and it
induced a slight but significant reduction in resting heart rate
(Fig. 2C). Thus, in addition to stimulating skeletal muscle Akt
activity and muscle hypertrophy, ursolic acid improved exercise
capacity, lowered resting heart rate and did not alter blood
pressure.
Ursolic acid reduces diet-induced obesity, glucose
intolerance and fatty liver disease
Previous studies showed that skeletal muscle Akt activation [8]
and ursolic acid [14,15] reduce diet-induced obesity, white adipose
tissue, glucose intolerance and fatty liver disease. Similarly, we
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Figure 1. In mice fed a high fat diet, ursolic acid increases
skeletal muscle Akt signaling, anabolic mRNA expression, grip
strength, skeletal muscle mass, and fast and slow skeletal
muscle fiber size. Mice were provided ad libitum access to high fat
diet (HFD) lacking or containing 0.14% ursolic acid (UA) for 6 weeks.
Data are means 6 SEM. *P,0.05 by t-test. (A) Triceps muscles here
harvested and subjected to SDS-PAGE and immunoblot analysis with
anti-phospho(Ser473)-Akt and anti-Akt antibodies. Upper: representa-
tive immunoblots. Lower: Phospho-Akt (P-Akt) and total Akt levels were
quantitated with densitometry. In each mouse, the phospho-Akt/total
Akt ratio was normalized to the average phospho-Akt/total Akt ratio in
mice fed HFD lacking UA. n=5 mice per diet. (B) Quadriceps mRNA
levels were determined using qualitative real-time RT-PCR (qPCR).
Levels in UA-treated mice were normalized to the average levels in mice
fed HFD lacking ursolic acid, which were set at 1. n=10 mice per diet.
(C) Grip strength. n=10 mice per diet. (D) Weights of bilateral
quadriceps and triceps brachii (triceps). n$12 mice per diet. (E) Slow
and fast muscle fiber diameters. Sections of triceps muscle were
subjected to immunohistochemical analysis with anti-slow myosin and
anti-fast myosin antibodies, and then fiber diameter was measured.
Slow fibers: n$50 fibers/triceps from 5 mice per condition. Fast fibers:
n$100 fibers/triceps from 5 triceps per condition.
doi:10.1371/journal.pone.0039332.g001
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Figure 2. Ursolic acid increases exercise capacity, does not
alter blood pressure, and reduces resting heart rate in high fat-
fed mice. Mice were fed high fat diet (HFD) lacking or containing
0.27% ursolic acid (UA) for 17 weeks, and then exercise treadmill
capacity was determined according to an established protocol [36] (A)
and resting blood pressure and heart rate were determined with tail
cuff plethysmography (B and C). Data are means 6 SEM from $7 mice
per diet. P-values were determined with t-tests. *P,0.05.
doi:10.1371/journal.pone.0039332.g002
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PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e39332found that mice that consumed high fat diet containing ursolic
acid gained less weight than mice that consumed high fat diet
without ursolic acid (Fig. 3A; Fig. S1). In addition, ursolic acid-
treated mice had smaller epididymal and retroperitoneal fat pads
(Fig. 3B; Fig. S1). These data indicated that ursolic acid reduced
obesity. To evaluate glucose homeostasis, we measured fasting
blood glucose. In the absence of ursolic acid treatment, fasting
blood glucose was elevated at 109 6 2 mg/dl (Fig. 3C). However,
fasting blood glucose was normal (74 6 5 mg/dl) in ursolic acid-
treated mice (Fig. 3C). In addition to preventing fasting
hyperglycemia, ursolic acid reduced glycemic excursion during a
glucose tolerance test (Fig. 3D; Fig. S1). Thus, ursolic acid reduced
both obesity and glucose intolerance.
In addition to glucose intolerance, fatty liver disease is an
important complication of diet-induced obesity [23]. Ursolic acid
reduced liver weight (Fig. 4A; Fig. S1), hepatocellular steatosis
(Figs. 4B and 4C) and hepatic triglyceride content (Fig. 4D); these
data indicated reduced fatty liver disease. Ursolic acid also reduced
plasma aminotransferases (Fig. 4E), suggesting reduced hepatocyte
injury. At the molecular level, ursolic acid reduced the steady-state
level of Srebpf1 mRNA (Fig. 4F), which encodes SREBP-1c, a
transcription factor that promotes lipogenesis and fatty liver
disease [24,25]. Accordingly, ursolic acid reduced expression of
three key SREBP-1 target genes (acetyl-CoA carboxylase 1 (Acaca), fatty
acid synthase (Fasn) and stearoyl Co-A desaturase-1 (Scd1)) (Fig. 4F), and
it markedly reduced the level of acetyl-CoA carboxylase 1 (ACC)
protein (Fig. 4G). In contrast, ursolic acid did not alter the levels of
mRNA encoding SREBP-2 (Srebpf2) or SREBP-2-dependent
mRNAs involved in cholesterol synthesis (3-hydroxy-3-methylglu-
taryl-CoA synthase-1 (Hmgcs1) and 3-hydroxy-3-methylglutaryl-
CoA reductase (Hmgcr) (Fig. 4F). Thus, ursolic acid reduced
obesity, glucose intolerance and fatty liver disease. All of these
effects were consistent with increased skeletal muscle Akt activity
[8].
Ursolic acid increases brown fat
The interscapular fat pad contains two types of fat: white fat,
which stores energy, and brown fat, which expends energy to
generate heat and maintain body temperature. Importantly,
brown fat shares developmental origins with skeletal muscle [26]
and opposes the development of obesity [27]. Ursolic acid reduced
interscapular white fat (Fig. 5A; Fig. S1), consistent with its effects
on epididymal and retroperitoneal white fat (Fig. 3B). In contrast,
ursolic acid increased interscapular brown fat (Fig. 5A). As an
additional test, we measured expression of uncoupling protein 1
(UCP1), a brown fat marker, and found that ursolic acid increased
UCP1 (Fig. 5B). Since brown fat is thermogenic, we hypothesized
that ursolic acid-treated mice might be resistant to hypothermia.
Indeed, ursolic acid reduced the decline of core body temperature
at 4uC (Fig. 5C). Thus, in addition to increasing skeletal muscle,
ursolic acid also increased brown fat.
Ursolic acid increases energy expenditure
Since skeletal muscle and brown fat have relatively high rates of
energy expenditure [28], we hypothesized that ursolic acid might
increase energy expenditure. To test this, we used a system that
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Figure 3. Ursolic acid reduces diet-induced obesity and glucose intolerance. Mice were provided ad libitum access to high fat diet (HFD)
lacking or containing 0.14% ursolic acid (UA) for 6 weeks. Data are means 6 SEM. *P,0.05 by t-test. (A) Total body weight was measured at the
indicated times. n$12 mice per diet. (B) Weights of bilateral epididymal and retroperitoneal fat pads. n=10 mice per diet. (C) Fasting blood glucose
levels. Mice were fasted for 16 h prior to tail vein glucose measurements. n$12 mice per diet. (D) Glucose tolerance tests. Following a 16 h fast, 1 g/
kg glucose was administered by i.p. injection at time =0 min. Blood glucose was then measured via the tail vein at the indicated times. n=10 mice
per diet. Left, blood glucose values. Right, areas under the curves.
doi:10.1371/journal.pone.0039332.g003
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e39332also permitted simultaneous measurements of food intake and
spontaneous activity. We studied mice that had consumed high fat
food lacking or containing ursolic acid for either 3 days or
6 weeks. By testing both acute (3 days) and chronic (6 weeks)
treatments, we could examine ursolic acid’s effects before and after
it altered body composition.
One potential mechanism of obesity resistance is reduced food
intake. However, acute treatment with ursolic acid did not alter
food intake (Fig. 6A). Moreover, chronic treatment with ursolic
acid increased food intake during the dark period, when mice are
more active (Fig. 6A). These data ruled out reduced food intake as
the mechanism of obesity reduction. In addition, increased food
intake in the setting of obesity resistance was consistent with
increased energy expenditure.
Fig. 6B shows the effects of acute and chronic ursolic acid
treatment on energy expenditure. Acute treatment with ursolic
acid had no effect (Fig. 6B). However, chronic treatment with
ursolic acid significantly increased energy expenditure during both
dark and light cycles (Fig. 6B) without significantly altering
spontaneous activity (Fig. S2). These data indicated that ursolic
acid reduced obesity by increasing resting energy expenditure.
Furthermore, increased energy expenditure required chronic
treatment with ursolic acid, which could be consistent with a
requirement for skeletal muscle and brown fat growth.
Discussion
Ursolic acid is contained in many edible fruits and herbs [3,4].
We previously found that ursolic acid enhances skeletal muscle
insulin/IGF-I signaling, leading to Akt activation, muscle hyper-
trophy, and reduced adiposity and blood glucose [5]. In the
current study, we investigated ursolic acid’s effects in the setting of
a high fat diet, where muscle Akt activity is known to increase
energy expenditure and reduce obesity and its complications [8].
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39332We found that ursolic acid increased muscle Akt activity in high
fat-fed mice. Moreover, as predicted by previous studies of
transgenic mice expressing a constitutively active Akt construct
specifically in skeletal muscle [8], the ursolic acid-mediated
increase in skeletal muscle Akt activity was associated with skeletal
muscle hypertrophy, increased energy expenditure, and reduced
total body weight, white fat, glucose intolerance and hepatic
steatosis.
Interestingly, we found that ursolic acid also increased brown
fat, whose high rate of energy expenditure provides protection
against obesity [27]. Although ursolic acid’s effect on skeletal
muscle is potentially sufficient to explain ursolic acid’s effects on
energy expenditure, thermogenesis, white fat, liver and glucose
homeostasis [8,29], we speculate that increased brown fat may also
play an important role. We suggest a general model in which
ursolic acid increases skeletal muscle and brown fat, leading to
increased energy expenditure, and thus resistance to diet-induced
obesity, fatty liver disease and glucose intolerance. This model
provides a framework for further studies, including FDG-PET-
CT-imaging to determine if the brown fat in ursolic acid-treated
mice is metabolically active, and studies to determine whether
ursolic acid affects brown fat, white fat and liver by direct or
indirect mechanisms.
How ursolic acid increases brown fat remains uncertain. One
possibility is that increased brown fat is a secondary effect of
reduced insulating white fat. Another possibility is that ursolic acid
increases sympathetic activity, which is known to expand brown
fat [30]. Our findings that ursolic acid slightly decreased the
resting heart rate, and did not alter blood pressure seem to argue
against a systemic increase in sympathetic activity. However,
sympathetic outflow to brown fat can be dissociated from
sympathetic outflow to other tissues [31,32]. Thus, it will be
important to directly measure whether ursolic acid alters
sympathetic outflow to brown fat.
A third possibility is that ursolic acid directly acts on brown fat
to stimulate its growth. Ursolic acid increases skeletal muscle at
least in part by enhancing ligand-dependent autophosphorylation
of the IGF-I and insulin receptors [5]. Since brown fat and skeletal
muscle arise from the same precursor cells [26], and since insulin/
IGF-I signaling promotes brown fat growth [33], it is tempting to
speculate that ursolic acid increases brown fat and skeletal muscle
through a common molecular mechanism. This mechanism could
involve multiple receptors based on a recent proteomic study
showing that a closely related oleanane triterpenoid bound .500
proteins in HEK293 cells, including proteins involved in insulin/
IGF-I signaling, AMP kinase signaling, JAK/Stat signaling, NFkB
signaling and retinoic acid signaling [34]. It was therefore
suggested that oleanane triterpenoids are multifunctional small
molecules with many low affinity but biologically relevant targets
[34]. Perhaps the same is true for other bioactive triterpenoids,
such as ursolic acid. This is a challenging but important area for
future investigation.
Other important areas for future investigation include studies to
determine whether ursolic acid’s effects on skeletal muscle mRNA
expression (e.g. increased Hk2, Vegfa and Igf1) represent a reversal
of changes that are induced by high fat feeding. It will also be
interesting to determine whether ursolic acid might limit the
induction of mRNAs that are typically induced in fatty liver (such
as Cd36, Mogat1 and Pparg), and whether higher or lower doses of
ursolic acid might have differential effects on skeletal muscle,
brown fat, white fat and liver.
In summary, we found that ursolic acid increases skeletal
muscle, brown fat and energy expenditure in a mouse model of
diet-induced obesity. These effects are associated with increased
strength and exercise capacity, and reduced obesity, improved
glucose tolerance and decreased hepatic steatosis. These pre-
clinical data recommend further studies in humans. If ursolic acid
has similar effects in mice and humans, then ursolic acid and/or
structural analogs might be useful therapeutic agents for a number
of increasingly common metabolic disorders, including skeletal
muscle atrophy, obesity, type 2 diabetes and non-alcoholic fatty
liver disease.
Materials and Methods
Ethics Statement
All experiments conformed to the National Institutes of Health
Guide for the Care and Use of Laboratory Animals and were
approved by the University of Iowa Institutional Animal Care and
Use Committee. This protocol was approved under application
number 1002026.
Animals and diets
All studies utilized 6–8 week old male C57BL/6 mice, which
were obtained from NCI and used for experiments within 3 weeks
of their arrival. Prior to experiments, mice were maintained on
standard chow (Harlan Teklad formula 7013). The high fat diet
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Figure 6. Chronic, but not acute, ursolic acid treatment
increases food intake and energy expenditure. Mice were fed
high fat diet (HFD) lacking or containing 0.27% ursolic acid (UA) for
either 3 days (acute treatment) or 6 weeks (chronic treatment), and
then food intake (A) and energy expenditure (B) were determined using
a comprehensive lab animal monitoring system (CLAMS). Left panels:
hourly measurements. Data are means from 12 mice per diet. Right
panels: cumulative measurements during the dark and light periods.
Data are means 6 SEM from 12 mice per diet. P-values were
determined with unpaired t-tests. *P,0.05.
doi:10.1371/journal.pone.0039332.g006
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of calories from fat. Ursolic acid was obtained from Enzo Life
Sciences, and then sent to Harlan Teklad for incorporation into
HFD. Mice were housed at 21uC except during the cold tolerance
test, and 12 h light/12 h dark cycles were maintained throughout
the study. Mice were colony caged except during CLAMS
monitoring and for 2 days prior to and during the cold tolerance
test, when mice were individually housed. Altogether, we
performed seven independent experiments to test and confirm
the effects of either 0.14% or 0.27% ursolic acid. Sample sizes for
each experiment are described in the corresponding figure
legends.
Immunoblot analysis
Tissue samples were snap frozen in liquid N2, and then Triton-
X 100 soluble protein extracts were prepared as previously
described [5]. An aliquot of each extract was mixed with 0.2
volumes of sample buffer (250 mM Tris-HCl, pH 6.8, 10% SDS,
25% glycerol, 0.2% (w/v) bromophenol blue, and 5% (w/v) 2-
mercaptoethanol) and heated for 5 min at 95uC, whereas a
separate aliquot was used to determine protein concentration by
the BCA kit (Pierce). Samples (25 mg) were subjected to SDS-
PAGE, then transferred to Hybond-C extra nitrocellulose filters
(Millipore). Immunoblots were performed at 4uC for 16 h using a
1:2000 dilution of antibodies detecting total Akt, phospho-Akt
(Ser473), ACC, or a-tubulin (all from Cell Signaling); UCP1
(Abcam); or actin (Santa Cruz).
Quantitative Real-Time RT-PCR
Tissue samples were immediately placed in RNAlater (Ambion)
and stored at 280uC until further use. Total RNA was extracted
using TRIzol solution (Invitrogen). TRIzol-extracted mRNA was
treated with DNase I using the Turbo DNA-free kit (Ambion).
qPCR analysis of Igf1, Hk2, Vegfa, Srebpf1, Acaca, Fasn, Scd1, Srebpf2,
Hmgcs1 and Hmgcr was performed using TaqMan Gene Expression
Assays (Applied Biosystems). First strand cDNA was synthesized
from 2 mg of RNA using the High Capacity cDNA Reverse
Transcription Kit (part no. 4368814; Applied Biosystems). The
real time PCR contained, in a final volume of 20 ml, 20 ng of
reverse transcribed RNA, 1 ml of 20X TaqMan Gene Expression
Assay, and 10 ml of TaqMan Fast Universal PCR Master Mix
(part no. 4352042; Applied Biosystems). qPCR was carried out
using a 7500 Fast Real-Time PCR System (Applied Biosystems) in
9600 emulation mode. All qPCR reactions were performed in
triplicate and the cycle threshold (Ct) values were averaged to give
the final results. To analyze the data, we used the DCt method,
with level of 36B4 mRNA serving as the invariant control.
Grip strength measurements
Forelimb grip strength was determined using a grip strength
meter equipped with a triangular pull bar (Columbus Instruments).
Each mouse was subjected to 5 consecutive tests to obtain the peak
value.
Skeletal muscle fiber analysis
Triceps muscles were fixed in 10% neutral buffered formalin,
embedded in paraffin, and then sectioned with a Microm
HM355S motorized microtome (Microm, Walldorf, Germany).
Slides were treated with Proteinase K for 5 min (fast myosin) or
10 min (slow myosin). Slides were blocked with 10% goat serum
for 60 min, then treated with a 1:500 dilution of primary antibody
(Sigma-Aldrich #M8421 (slow myosin) or Sigma-Aldrich
#M4276 (fast myosin)) in Dako diluent (Dako, #S0809). Slides
were next treated with Affinpure Fab Fragment Goat anti-Mouse
IgG (Jackson ImmunoResearch #115-007-003) diluted 1:500 in
10% goat serum for 30 min. Following this, slides were treated
with Biotin SP Fab Fragment Goat Anti-Mouse (Jackson
ImmunoResearch #115-066-072) diluted 1:500 in 10% goat
serum for 30 min. Signal was developed with DAB (Vector, SK-
4100) for 5 min at 22uC, then slides were rinsed once with 1x wash
buffer before adding DAB Enhancer (Vector, SK-4100) for 3 min.
Slides were then counterstained with hematoxylin (Surgipath) and
after air-drying for 20 min, coverslips were mounted with
Vectashield (Vector, #H-1400) before visualization with an
Olympus IX-71 microscope equipped with a DP-70 camera.
Image analysis was performed using ImageJ software, and
myofiber diameter was measured using the lesser diameter
method, as described elsewhere [35].
Exercise treadmill testing
Mice were acclimated to a motor-driven open treadmill set at
14 M/min at 0% grade and a shock grid set at 0.2 mA (Columbus
Instruments model #1055MSD) for 5 min per day for 2 days. On
the following day, exercise tolerance was determined at a constant
treadmill incline of 10% as described previously [36]. For the first
5 min, the treadmill was set 10 M/min. We then increased the
speed by 2 M/min every 2 min. The test was terminated when
mice contacted the shock grid for 10 seconds.
Heart rate and blood pressure
Mice were acclimated to tail cuff plethysmography (BP-2000,
Visitech Systems) 3 times weekly for 2 weeks before heart rate and
blood pressure measurements were obtained.
Glucose tolerance tests
Mice were acclimated to human handling weekly for 6 weeks,
then fasted for 16 h (from 1700 to 0900 h). Blood glucose was then
obtained from the tail vein with an Accucheck Aviva glucose
meter. Mice then received an i.p. injection of glucose (1 g/kg body
weight) and blood glucose was measured 15, 30, 60 and 120 min
later.
Liver histology, lipid analysis and plasma
aminotransferase measurements
Liver tissue was fixed in 10% neutral buffered formalin,
embedded in paraffin, sectioned with a Microm HM355S
motorized microtome (Microm, Walldorf, Germany), and then
stained with hematoxylin and eosin or with osmium. For osmium
staining, sections were incubated in 2% (w/v) osmium tetroxide
and 5% (w/v) potassium dichromate for 7 hours at 22uC, followed
by a 2 hour tap water rinse. Osmium stained tissues were routinely
processed, paraffin embedded, sectioned and stained with neutral
red. Sections were examined on an Olympus IX-71 microscope
equipped with a DP-70 camera. For lipid analysis, liver samples
were snap frozen in liquid N2, and then shipped to Vanderbilt
Mouse Metabolic Phenotyping Core, where lipid levels were
measured as described previously [37,38]. Mouse plasma AST and
ALT were measured using the VITROS 350 Chemistry System.
Cold tolerance tests
Mice were acclimated to a rectal temperature probe (Oakton
Instruments) every other day for one week, and then fed HFD
lacking or containing 0.14% ursolic acid for 6 weeks. Mice were
then moved to individual cages for two days before starting the
test. On the day of the test, a baseline rectal temperature
measurement was obtained at 21uC. Mice were then transferred
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measured hourly.
Analysis of energy expenditure, food intake and activity
Mice were moved to comprehensive lab animal monitoring
systems (CLAMS; Columbus Instruments) at 1800 h and accli-
mated to the CLAMS for 54 h. We then obtained food intake,
indirect calorimetry, and X- and Y-axis activity measurements
over the next 24 h. Activity was defined as $2 beam-breaks in one
axis within a 30 sec period. The light/dark cycle and temperature
were constant before and during CLAMS.
Supporting Information
Figure S1 In high fat-fed mice, 0.27% ursolic acid
increases skeletal muscle and brown fat while reducing
obesity, glucose intolerance and fatty liver disease. Mice
were provided ad libitum access to high fat diet (HFD) lacking or
containing 0.27% ursolic acid (UA) for 6 weeks. Data are means 6
SEM from $7 mice per diet. *P,0.05 by t-test. (A) Grip strength.
(B) Weights of bilateral quadriceps and triceps. (C) Total body
weight. (D) Weight of bilateral epididymal and retroperitoneal fat
pads. (E) Fasting blood glucose. (F) Intraperitoneal glucose
tolerance tests. (G) Liver weight. (H) Weight of bilateral
interscapular white and brown fat components.
(EPS)
Figure S2 Ursolic acid treatment does not alter sponta-
neous activity. Mice were fed high fat diet (HFD) lacking or
containing 0.27% ursolic acid (UA) for either 3 days (acute
treatment) or 6 weeks (chronic treatment), and then spontaneous
activity in the X- and Y-axes was determined using a
comprehensive lab animal monitoring system (CLAMS). Data
are means 6 SEM from 12 mice per diet. P-values were
determined with unpaired t-tests. *P,0.05. Left: hourly activity
measurements. Right: cumulative activity measurements during the
dark and light periods. In these experiments, we also measured
food intake and energy expenditure; those data are shown in Fig. 6.
(EPS)
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